#United States #Cancer Research #Bronx #Montefiore Einstein #Ulrich Steidl

Ulrich Steidl Takes the Helm at Montefiore Einstein Comprehensive Cancer Center

The Montefiore Einstein Comprehensive Cancer Center (MECCC) has officially welcomed Dr. Ulrich Steidl, M.D., Ph.D., as its new director. This appointment comes after Dr. Steidl served as the interim director since late 2025. Renowned globally for his contributions to blood cancer and stem cell research, Dr. Steidl's leadership is expected to significantly impact cancer care and research at the Bronx-based facility.

In his acceptance statement, Dr. Steidl expressed immense gratitude and excitement about leading MECCC. "I am deeply honored to accept this leadership role at MECCC," he said, emphasizing his commitment to the center's mission of advancing cancer treatment and innovative science. "We have a tremendous team dedicated to our patients and our community. I look forward to our collaborative efforts in reducing the burden of cancer not only in the Bronx but beyond."

Dr. Steidl has unique qualifications for this position. Having been part of the Montefiore Einstein team since 2008, he held several critical roles, including associate director for basic science and deputy director. His expertise is grounded in both basic and translational research, with his work focusing on the characterization of pre-leukemic stem cells and understanding their progression to leukemic stem cells. Dr. Steidl has been pivotal in developing therapies that interrupt this progression, with his discoveries leading to numerous experimental drugs now in clinical trials.

His impressive track record of research has yielded significant findings, positioning him among the first researchers to identify pre-cancerous stem cells and elucidate the origins of myelodysplastic syndrome, a precursor to acute myeloid leukemia. This knowledge has sparked innovations in cancer prevention strategies and tailored treatments for various cancer types.

Dr. Steidl's expertise is not just recognized in research; it extends to mentorship as well. He has mentored many graduate and postdoctoral trainees, several of whom have ascended to influential positions in notable institutions worldwide. His commitment to education and cultivating future scientific leaders has been acknowledged through numerous accolades, including Einstein's Saul R. Korey Award in Translational Science and Medicine in 2020 and the 2025 McCulloch-Till Award from the International Society for Experimental Hematology.

The appointment comes at a time when MECCC is poised to enhance its status as a National Cancer Institute (NCI)-designated comprehensive cancer center. This designation underscores the center's dedication to cancer research and clinical care, particularly within the diverse community of the Bronx. Since its inception in 1971, MECCC has been at the forefront of cancer research and care, integrating exceptional sciences from the Albert Einstein College of Medicine with a multidisciplinary approach to patient care through the Montefiore Health System.

With Dr. Steidl's dynamic leadership, MECCC aims to continue redefining excellence in cancer care and research, focusing on reducing cancer's burden through education, outreach, and innovative treatments. As the center moves forward under his guidance, the future looks promising for both patients and practitioners engaged in the fight against cancer.